Noordijk EM, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol. 2005;23(16_suppl):6505–6505.
Engert A, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.
•• Radford J, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607. UK NCI RAPID response-adapted trial. Addition of RT to ABVD × 4 for PET negative patients resulted in 6% improvement in 3-year EFS.
•• Andre ́ M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017. doi:10.1200/JCO.2016.68.6394. Patients with early-stage favorable and unfavorable HL with negative interim PET following ABVD randomized to ± XRT. Radiotherapy randomization stopped early by DSMC when significant improvement in PFS demonstrated with CMT.
Meyer RM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399–408.
Hay AE, et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2013;24(12):3065–9.
Herbst C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95(3):494–500.
Koshy M, et al. Declining use of radiotherapy in stage I and II Hodgkin’s disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys. 2012;82(2):619–25.
Parikh RR, et al. Early-stage classic Hodgkin lymphoma: the utilization of radiation therapy and its impact on overall survival. Int J Radiat Oncol Biol Phys. 2015;93(3):684–93.
Aleman BM, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–406.
•• Johnson PW, et al. Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010;28(20):3352–9. Study evaluating ABVD vs alternate multi-drug chemo in patients with bulky stage II, or stage III or IV. RT was recommended for patients who presented with bulky adenopathy or who failed to achieve a complete response by CT. XRT utilization associated with significant improvement in 5-year PFS and OS.
Eich HT, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD11 trial. J Clin Oncol. 2010;28(27):4199–206.
Engert A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9.
Krasin MJ, et al. Patterns of treatment failure in pediatric and young adult patients with Hodgkin’s disease: local disease control with combined-modality therapy. J Clin Oncol. 2005;23(33):8406–13.
Picardi M, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48(9):1721–7.
Johnson P, Federico M, Fossa A, Barrington S, Kirkwood A, Roberts T, et al., Response rates and toxicity of response-adapted therapy in advanced Hodgkin lymphoma: Initial results from the international RATHL study. Haematologica. 2013;98(s2).
Dhakal S, et al. Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2009;75(1):188–92.
Dharmarajan KV, et al. Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the children’s oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):60–6.
•• Specht L, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–62. International consensus guidelines for target delineation with involved site radiotherapy (ISRT)
Girinsky T, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79(3):270–7.
Maraldo MV, et al. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(4):1057–65.
Paumier A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;80(1):199–205.
Kriz J, et al. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study group. Int J Radiat Oncol Biol Phys. 2015;92(1):46–53.
Weber DC, et al. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys. 2011;81(2):490–7.
Hodgson DC, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer. 2007;110(11):2576–86.
Schaapveld M, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–511.
Giri S, et al. Incidence of breast cancer among female survivors of Hodgkin lymphoma: a US-population-based trend analysis from 1973 to 2011. Blood. 2015;126(15):1861–3.
• Conway JL, et al. Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017;97(1):35–41. Large population database study demonstrating no increased risk of breast cancer development with small-volume mediastinal radiotherapy.
Ibrahim EM, et al. Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis. BMC Cancer. 2012;12:197.
Castellino SM, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806–16.
Eriksson F, et al. Long-term cardiac mortality following radiation therapy for Hodgkin’s disease: analysis with the relative seriality model. Radiother Oncol. 2000;55(2):153–62.
Ng AK, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101–8.
van Nimwegen FA, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235–43.
Swerdlow AJ, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206–14.
Paumier A, et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(4):1522–7.
Aznar MC, et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys. 2015;92(1):169–74.
Cella L, et al. Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. Radiat Oncol. 2013;8:22.
Inskip PD, et al. Radiation-related new primary solid cancers in the Childhood Cancer Survivor Study: comparative radiation dose response and modification of treatment effects. Int J Radiat Oncol Biol Phys. 2016;94(4):800–7.
Voong KR, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol. 2014;9:94.
Andolino DL, et al. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin’s lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys. 2011;81(4):e667–71.